Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C by Honda Masao et al.
Hepatic ISG expression is associated with
genetic variation in interleukin 28B and the
outcome of IFN therapy for chronic hepatitis C
著者 Honda Masao, Sakai Akito, Yamashita Tatsuya,
Nakamotoa Yasunari, Mizukoshi Eishiro, Sakai
Yoshio, Yamashita Taro, Nakamura Mikiko,
Shirasaki Takayoshi, Horimoto Katsuhisa,
Tanaka Yasuhito, Tokunaga Katsushi, Mizokami















Hepatic ISG expression is associated with genetic variation in IL28B 
and the outcome of IFN therapy for chronic hepatitis C 
 
Running title: Hepatic expression of ISGs and IFN therapy 
 
Masao Honda1) 2), Akito Sakai1), Tatsuya Yamashita1), Yasunari Nakamoto1), Eishiro Mizukoshi1), 
Yoshio Sakai1), Taro Yamashita1), Mikiko Nakamura1), Takayoshi Shirasaki2), Katsuhisa 
Horimoto3), Yasuhito Tanaka4), Katsushi Tokunaga5), Masashi Mizokami4), Shuichi Kaneko1) 
and Hokuriku Liver Study Group* 
 
1) Department of Gastroenterology, Kanazawa University Graduate School of Medicine, 
Kanazawa, Japan 
2) Department of Advanced Medical Technology, Kanazawa University Graduate School of 
Health Medicine, Kanazawa, Japan 
3) Biological Network Team, Computational Biology Research Center, National Institute of 
Advanced Industrial Science and Technology, Japan 
4) Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate 
School of Medicine, Nagoya, Japan 
5) Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, 
Tokyo, Japan 
 
*Participating investigators are listed in Appendix A. 
 
The authors declare that no potential competing interests exist. 
 
Abbreviations: CH-C, Chronic Hepatitis C; HCV, Hepatitis C Virus; IFN, Interferon; IL, 
Interleukin; ISDR, Interferon Sensitivity Determining Region; ISGs, Interferon Stimulated 







Honda et al 
 
 - 2 -  
Each author was involved with the manuscript as follows: 
Masao Honda1) 2): analysis and interpretation of data; drafting of the manuscript 
Akito Sakai1): acquisition of data 
Tatsuya Yamashita1): acquisition of data 
Yasunari Nakamoto1): critical revision of the manuscript for important intellectual content 
Eishiro Mizukoshi1): acquisition of data 
Yoshio Sakai1): acquisition of data 
Taro Yamashita1): acquisition of data 
Mikiko Nakamura1): technical support 
Takayoshi Shirasaki2): technical support 
Katsuhisa Horimoto3): statistical analysis of clinical data and gene expression 
Yasuhito Tanaka4): acquisition of data of genetic variation of IL28B 
Katsushi Tokunaga5): acquisition of data of genetic variation of IL28B 
Masashi Mizokami4): acquisition of data of genetic variation of IL28B 
Shuichi Kaneko1): study concept and design 
 
Corresponding author:  
Shuchi kaneko, M.D., Ph.D. 
Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, 
Takara-Machi 13-1, Kanazawa 920-8641, Japan  
Tel: +81-76-265-2235; Fax: +81-76-234-4250 
E-mail: skaneko@m-kanazawa.jp 
Honda et al 
 
 - 3 -  
Abstract  
Objective: Multiple viral and host factors are related to the treatment response to 
pegylated-interferon (Peg-IFN) and ribavirin (RBV) combination therapy; however, the clinical 
relevance and relationship of these factors have not yet been fully evaluated.  
Methods: We studied 168 patients with chronic hepatitis C who received Peg-IFN and RBV 
combination therapy. Gene expression profiles in the livers of 91 patients were analyzed using 
an Affymetrix genechip. The expression of interferon-stimulated genes (ISGs) was evaluated 
in all samples by real-time PCR. Genetic variation in interleukin 28B (IL28B; rs8099917) was 
determined in 91 patients.  
Results: Gene expression profiling of the liver differentiated patients into two groups: patients 
with up-regulated ISGs (Up-ISGs) and patients with down-regulated ISGs (Down-ISGs). A 
high proportion of patients with no response (NR) to treatment was found in the Up-ISGs 
group (p=0.002). Multivariate logistic regression analysis showed that ISGs (<3.5) 
(Odds=16.2, p<0.001), fibrosis stage (F1-2) (Odds=4.18, p=0.003), and ISDR mutation (≧2) 
(Odds=5.09, p=0.003) were strongly associated with the viral response. The IL28B 
polymorphism of 91 patients showed that 66% were major homozygotes (TT), 30% were 
heterozygotes (TG), and 4% were minor homozygotes (GG). Interestingly, hepatic ISGs were 
associated with the IL28B polymorphism (Odds=18.1, p<0.001) and its expression was 
significantly higher in patients with the minor genotype (TG or GG) than in those with the 
major genotype (TT). 
Conclusions: The expression of hepatic ISGs is strongly associated with treatment response 
and genetic variation of IL28B. The differential role of host and viral factors as predicting 
factors may also be present.  
Keywords: Pegylated interferon, Ribavirin, Gene expression, Single Nucleotide 
Polymorphism 
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Introduction 
 A human liver infected with hepatitis C virus (HCV) develops chronic hepatitis, 
cirrhosis, and in some instances, hepatocellular carcinoma (HCC).1 Interferon (IFN) and 
ribavirin (RBV) combination therapy is a popular modality for treating patients with chronic 
hepatitis C (CH-C); approximately 50% of patients usually relapse, particularly those with HCV 
genotype 1b and a high viral load.2, 3 Therefore, it is beneficial to predict the response of 
patients with the 1b genotype and a high viral load to polyethylene glycol-IFN (Peg-IFN) and 
RBV combination therapy before starting treatment because therapy can be long, costly, and 
have many side effects. Amino acid (aa) substitutions in the interferon sensitivity determining 
region (ISDR), located in the HCV nonstructural region 5A, are useful for predicting the 
response of patients with genotype 1b to IFN therapy.4 However, viral factors alone do not 
sufficiently predict the outcome of treatment in every case.5 
 In addition to viral factors, hepatic gene expression before and during IFN treatment 
has been examined to determine host factors associated with the response to treatment.6, 7 
Interferon-stimulated genes (ISGs) upregulated in the liver prior to treatment might be related 
to the poor induction of ISGs and the impaired eradication of HCV during treatment.6–9 This 
may be because the ISGs have already been maximally induced before treatment. However, 
the clinical relevance of the expression of ISGs as predictive factors for the outcome of 
treatment has not yet been fully evaluated.  
 In parallel to gene expression analysis, genome-wide association studies (GWAS) 
have been used to identify loci associated with the response to treatment; genetic variation in 
interleukin 28B (IL28B) was found to predict hepatitis C treatment-induced viral clearance.10-12  
In this study, with a relatively large cohort of CH-C patients treated with Peg-IFN and 
RBV, we validated the clinical relevance of the expression of hepatic ISGs as predictive 
factors for the outcome of treatment. In addition, we demonstrated that the expression of 
hepatic ISGs was closely related to genetic variation in IL28B.   
Honda et al 
 
 - 5 -  
Materials and Methods 
Patients 
We enrolled 168 patients with CH-C at the Graduate School of Medicine, Kanazawa 
University Hospital and its related hospitals, Japan (Table 1, Supplemental Table 1). The 
cohort included 92 men and 76 women, ranging from 21–73 years of age, who were 
registered prospectively in 2005 and 2007. All patients had HCV genotype 1b and high viral 
loads (≥100 KIU/ml) measured by quantitative Cobas Amplicor assays (Roche Diagnostics Co. 
Ltd., Tokyo, Japan). All patients had undergone liver biopsy before combination therapy. 
Exclusion criteria for patients not eligible for Peg-IFN and RBV combination therapy were as 
follows: (1) pregnant women or women of child-bearing potential, nursing mothers, or male 
patients whose partner might become pregnant; (2) patients with hepatocellular carcinoma; 
(3) patients with serious complications in the heart, kidneys, or lungs; (4) patients with 
autoimmune diseases, such as autoimmune hepatitis, and primary biliary cirrhosis; and (5) 
patients infected with the hepatitis B virus. Informed consent was obtained from all patients 
and ethics approval for the study was obtained from the ethics committee for human 
genome/gene analysis research at Kanazawa University Graduate School of Medical 
Science.  
All patients were administered Peg-IFN-α 2b (Schering-Plough K.K., Tokyo, Japan) 
and RBV combination therapy for 48 wk. Peg-IFN was given in weekly doses and adjusted to 
body weight according to the manufacturer’s instructions (45 kg or less, 60 µg/dose; 46–60 kg, 
80 µg/dose; 61–75 kg, 100 µg/dose; 76–90 kg, 120 µg/dose; and 91 kg or more, 150 µg/dose). 
Similarly, RBV (Schering-Plough K.K.) was administered in daily doses adjusted to body 
weight according to the manufacturer’s instructions (60 kg or less, 600 mg/day; 61–80 kg, 800 
mg/day; and 81 kg or more, 1,000 mg/day). 
The final outcome of treatment was assessed 24 wk after the cessation of 
combination therapy. We defined treatment outcomes according to the decrease in viremia as 
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follows: sustained viral response (SVR), clearance of HCV viremia 24 wk after the cessation 
of therapy; transient response (TR), no detectable HCV viremia at the cessation of therapy 
but relapsed during the follow-up period; and no response (NR), HCV viremia detected at the 
cessation of therapy. An early virological response (complete EVR) was defined as 
undetectable HCV RNA in the serum by 12 wk. HCV genotypes were determined according to 
the method of Ohno et al. Serum HCV RNA was determined using qualitative and quantitative 
COBAS Amplicor assays (Roche Diagnostics Co., Ltd., Tokyo, Japan). The grading and 
staging of chronic hepatitis were histologically assessed according to the method of Desmet 
et al. (Table 1).13 
 
Preparation of liver tissue samples 
Liver biopsy samples were taken from all patients before treatment. The biopsy 
samples were divided into two parts: the first part was immersed in formalin for histological 
assessment and the second was immediately immersed in RNAlater (QIAGEN, Valencia, CA, 
USA) for RNA isolation. Liver tissue RNA was isolated using the RNeasy Mini kit (QIAGEN) 
according to the manufacturer’s instructions. Isolated RNA was stored at -70ºC until use.   
 
Affymetrix genechip analysis 
The quality of the isolated RNA was estimated after electrophoresis using an Agilent 
2001 Bioanalyzer (Palo Alto, CA, USA). Aliquots of total RNA (50 ng) isolated from the liver 
biopsy specimens were subjected to amplification using the WT-Ovation Pico RNA 
Amplification System (NuGen, San Carlos, CA, USA) according to the manufacturer’s 
instructions. Approximately 10 µg of cDNA was amplified from 50 ng of total RNA, and 5 µg of 
cDNA was used for fragmentation and biotin labeling using the FL-Ovation cDNA Biotin 
Module V2 (NuGen) according to the manufacturer’s instructions. Biotin-labeled cDNA was 
suspended in 220 µl of hybridization cocktail (NuGen) and 200 µl was used for hybridization to 
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the Affymetrix Human 133 Plus 2.0 microarray chip containing 54,675 probes. After stringent 
washing, the microarray chips were stained with streptavidin-phycoerythrin and probe 
hybridization was determined using a GeneChip Scanner 3000 (Affymetrix). Data files (CEL) 
were obtained using the GeneChip Operating Software 1.4 (Affymetrix).  
 
Hierarchical clustering and pathway analysis of genechip data 
Genechip data analysis was performed using BRB-Array Tools 
(http://linus.nci.nih.gov/BRB-ArrayTools.htm). The data were log-transferred, normalized, 
centered, and applied to the average linkage hierarchical clustering with centered correlation. 
For genechip analysis, we selected 37 representative ISGs. Hepatic gene expression profiling 
was obtained from 30 CH-C patients before and one week after the initiation of IFN and RBV 
combination therapy and the 100 most up-regulated genes were selected (submitted for 
publication). ISGs were suppressed in patients with a rapid viral response and up-regulated in 
patients with a slow viral response before treatment. Using the 100 treatment-induced genes, 
we evaluated hepatic gene expression in 30 patients before treatment. Hierarchical clustering 
analysis showed that a cluster of 37 ISGs was up-regulated in patients with a slow viral 
response. 
 Pathway analysis was performed using MetaCore (GeneGo, St. Joseph, MI, USA). 
Functional ontology enrichment analysis was performed to compare the Gene Ontology (GO) 
process distribution of differentially expressed genes (p < 0.01). 
 
Quantitative real-time detection (RTD)-PCR 
We performed quantitative real-time detection PCR (RTD-PCR) using TaqMan 
Universal Master Mix (PE Applied Biosystems, CA, USA). Primer pairs and probes for Mx1, 
OAS3, IFI44, IFI44L, OAS2, USP18, RSAD2, IFIT1, IFIH1, XAF1, CMPK2, EPSTI1, HERC6, 
PARP9, PLSCR1, and GAPDH were obtained from the TaqMan assay reagents library. Primer 
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pairs and probes for IL28B were designed as previously described.12 The standard curve was 
obtained in every assay using the RNA obtained from a normal liver.14, 15 The expression 
values were normalized by GAPDH and normalized values indicate the relative fold 
expression to a normal liver.  
 
Amino acid substitutions of ISDR in the nonstructural 5A region 
The nucleotide sequence of ISDR in the nonstructural 5A region (NS5A) was 
determined by direct sequencing of PCR amplified materials.4 Mutant-type ISDR was defined 
as containing two or more aa substitutions. 
 
Genetic variation of IL28B polymorphism  
A single nucleotide polymorphism (SNP) of IL28B was evaluated in 91 patients 
whose hepatic gene expression profiling was obtained. We genotyped 32 patients using 
Affymetrix Genome-Wide Human SNP Array 6.0 as previously described.12 The results for 
rs8105790, rs11881222, rs8099917, and rs7248668 were retrieved from a database to 
evaluate the association of these SNPs. rs1297986011 was determined by direct sequencing 
and rs8099917 was determined using TaqMan® Pre-Designed SNP Genotyping Assays as 
recommended by the manufacturer.  
 
Statistical analysis 
The Mann-Whitney U-test was used to analyze continuous variables. Chi-squared 
and Fisher’s exact tests were used for the analysis of categorical data.  
The overall plausibility of the treatment response groups was assessed using 
Fisher’s C statistic (Supplemental Table 2).16, 17 C is defined by C= -2Σ ln(pi), where pi is the 
probability (p-value) of each independent statement (clinical factors). C follows a chi-square 
distribution with 2k degrees of freedom, k being the number of independent statements 
(clinical factors).16 A non-significant C value means that the treatment response in the two 
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groups was not statistically independent.  
Multivariate analysis was performed using a stepwise logistic regression model. Each 
cut-off point for the continuous variables was decided by analysis of the receiver operating 
characteristic (ROC) curve. A p-value of less than 0.05 was considered significant. Statistical 
analyses were performed using JMP7 for Windows (SAS Institute, Cary, NC, USA) 
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Results 
 
Response rate and clinical characteristics 
 The clinical characteristics of the patients are shown in Table 1 and Supplemental 
Table 1. All of the patients were infected with HCV genotype 1b and had a high viral load 
(>100 IU/ml). No patients were co-infected with the hepatitis B virus (HBV). The 
intention-to-treat analysis showed that SVR, TR, and NR were observed in 70 (42%), 55 
(33%), and 43 (25%) patients, respectively (Supplemental Table 1). Before comparing 
patients with three different responses, the overall plausibility of the treatment response 
groups was assessed using Fisher’s C statistic. Fisher’s C statistic utilizes the p-values 
obtained by comparing pretreatment factors including age, gender, liver factors, laboratory 
parameters, and viral factors. As the SVR and TR groups could not be defined as different, 
they were grouped together and compared with NR (Table 1, Supplemental Table 2).  
Eleven patients with NR discontinued the therapy after 24 wk because of an 
insufficient effect, namely, serum HCV-RNA was still detectable at this time. The remaining 
patients completed 48 wk of Peg-IFN and RBV combination therapy. The administration rate 
of Peg-IFN with 80% or more was achieved in 67% of patients, and the administration rate of 
RBV with 80% or more was achieved in 60% of patients (Table 1).   
 
Analysis of hepatic gene expression 
 Prior to treatment, 91 of 168 patients (Supplemental Table 3) were randomly selected 
and their hepatic gene expression was determined using Affymetrix genechip analysis.  
Hierarchical clustering using 37 representative ISGs (see Materials and Methods) 
demonstrated two clear clusters of patients, one was a group composed of patients with 
up-regulated ISGs (Up-ISGs) and the other was a group consisting of patients with 
down-regulated ISGs (Down-ISGs) (Fig. 1). In patients with Up-ISGs, 21 (49%) showed NR, 
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while 8 (17%) patients with Down-ISGs showed NR (p=0.002). In contrast, 14 (33%) patients 
with Up-ISGs showed SVR, while 27 (56%) patients with Down-ISGs showed SVR (p=0.03). 
There were no significant differences in the frequency of advanced stages of liver fibrosis 
(F3-4) between patients with Up-ISGs and patients with Down-ISGs (18 (42%) and 17 (35%), 
respectively; p=0.664). These data indicated that the up-regulation of ISGs in the liver before 
treatment was strongly associated with resistance to IFN treatment. 
 
Host and viral factors associated with the response to combination therapy 
 To evaluate the multiple host and viral factors associated with the response to 
Peg-IFN and RBV combination therapy in all patients, univariate and multivariate analyses 
were performed. To assess the expression of hepatic ISGs, 15 genes (Mx1, OAS3, IFI44, 
IFI44L, OAS2, USP18, RSAD2, IFIT1, IFIH1, XAF1, CMPK2, EPSTI1, HERC6, PARP9, and 
PLSCR1) out of 37 representative ISGs were selected for their expression values of probe 
intensity and their expression was confirmed in liver tissue obtained from 168 patients by 
RTD-PCR. Although there were significant correlations of their expression with each other, 
except RARP9 and PLSCR1 (Supplemental Table 4), the dynamic range of gene expression 
was high for three genes, namely, myxovirus (influenza virus) resistance 1 interferon-inducible 
protein p78 (mouse) (Mx1), interferon-induced protein 44 (IFI44), and interferon-induced 
protein with tetratricopeptide repeats 1 (IFIT1) (Supplemental Fig. 1A). We averaged the 
expression values of Mx1, IFI44, and IFIT1 and used them for further study.    
 When we compared patients with SVR+TR and NR, the fibrosis stage of the liver 
(p=0.001), expression of hepatic ISGs (p<0.001), AST serum level (p=0.017), γ-GTP 
(p<0.001), LDL-Chol (p=0.019), and insulin (µU/ml) (p=0.039) were significantly different prior 
to treatment (Table 1). For treatment factors, the total dose and administration of IFN and RBV 
were not significantly different between these two groups. Early viral response (EVR) was 
observed in 101 (81%) patients and the proportion was significantly different (p<0.001) 
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between patients with SVR+TR and NR (Table 1).  
 Regression analysis of pretreatment factors showed a strong correlation among 
γ-GTP, ALT and AST, and HOMA-IR, FBS and insulin, and T-Chol, HDL-Chol, and LDL-Chol 
(data not shown). We selected fibrosis stage, ISGs, HCV-RNA, ISDR mutation, and BMI as 
factors for multivariate analysis. Stepwise multivariate logistic regression analysis was 
performed using the selected factors. From the ROC curve, we set the cut-off value for the 
expression of ISGs as 3.5 (Supplemental Fig. 1B). The results showed that expression of 
hepatic ISGs (<3.5), fibrosis stage (F1-2), and ISDR mutation ( ≧ 2) were significant 
pretreatment factors contributing to SVR+TR (Table 1). 
 
Clinical parameters associated with the expression of hepatic ISGs  
 Univariate and multivariate analyses revealed that the expression of hepatic ISGs 
was a strong predictor of the treatment outcome for SVR+TR patients. We next examined 
which clinical parameters were associated with the expression of hepatic ISGs (Table 2). 
Univariate analysis showed that the expression of ISGs was strongly correlated with the 
serum levels of γ-GTP (p<0.001) and AST (p<0.001), and weakly correlated with HCV-RNA, 
fasting blood sugar (FBS), insulin, HOMA-IR, triglyceride (TG), and LDL-Chol. Multivariate 
analysis showed that γ-GTP (p<0.001), HCV-RNA (p<0.001), and LDL-Chol (p=0.048) were 
significantly associated with hepatic ISGs. Noticeably, the expression of ISGs was negatively 
correlated with HCV-RNA in SVR+TR patients (p=0.009), while this correlation was not 
evident in NR patients (p=0.298) (Table 2, Supplemental Fig. 2). These results may indicate 
that endogenous ISGs suppress HCV in SVR+TR patients, while they are not active in NR 
patients. 
  
Expression of Hepatic ISGs before treatment is associated with genetic variation of 
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IL28B  
Recently, a GWAS successfully identified the genomic locus associated with the 
treatment response to Peg-IFN and RVB combination therapy for CH-C. Genetic variation in 
IL28B predicts HCV treatment-induced viral clearance.11–12 We determined the genetic 
variation in IL28B of 32 patients12 (Table 3). The SNPs rs8105790, rs11881222, rs8099917, 
and rs7248668 had a significant association with treatment response (odds ratio: 24.7–27.1, 
p=1.84×10-30–2.68×10-32). These SNPs are located in block 2 of the IL28B haplotype and 
show significant linkage disequilibrium in the HapMap data.12 Ge et al.11 reported a different 
SNP (rs12979860) that was located between rs11881222 and rs8099917. The nucleotide 
sequence of rs12979860 was determined by direct sequencing and the results are shown in 
Table 3. There was a strong association of rs12979860 and the other four SNPs indicating 
that this SNP was located within the same haplotype block. We confirmed these findings in 
multiple samples from Japanese patients (data not shown).   
We selected rs8099917 for further study and evaluated it using TaqMan® 
Pre-Designed SNP Genotyping Assays. The G nucleotide of rs8099917 was associated with 
a poor response to treatment (minor allele), while the T was associated with a fair response to 
treatment (major allele).12 Out of 91 patients (Supplemental Table 3), the proportion of major 
homozygotes (TT), heterozygotes (TG), and minor homozygotes (GG) were 66% (60/91), 
30% (27/91), and 4% (4/91), respectively (Table 4); 86% (51/60) of the major genotype (TT) 
patients had SVR or TR, while 65% (20/31) with the minor genotypes (TG or GG) had NR 
(p<0.001).  
Interestingly, hepatic gene expression profiles revealed that patients with the minor 
genotype showed higher expression of hepatic ISGs; while patients with the major genotype 
showed lower expression of hepatic ISGs (Figs. 2, 3). To further examine the relationship of 
the genetic variation in IL28B and its expression levels, we evaluated the expression of IL28B 
in the liver by RTD-PCR (Fig. 3). IL28B expression was approximately tenfold less than the 
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expression of ISGs. Although IL28B expression tended to be higher in some patients with the 
major genotype, there was no significant difference in IL28B expression in the liver between 
the major and minor genotypes (Fig. 3A). Nevertheless, the expression of ISGs was clearly 
high in patients with the minor genotype (p<0.0001) (Fig. 3B). IL28 activates STAT1 through 
downstream signaling from a heterodimeric class II cytokine receptor that consists of IL-10 
receptor β (IL-10Rβ) and IL-28 receptor α (IL-28Rα).18 19 Therefore, we examined the 
correlation between the expression of IL28B and ISGs. IL28B expression correlated with the 
expression of ISGs (r=0.44, p<0.001); however, the correlation was different according to the 
SNP genotype. We observed a steep-slope correlation for the minor genotype and a 
slow-slope correlation for the major genotype (Figs. 3C, D). Interestingly, four minor 
homozygotic (GG) patients showed a steeper correlation than the heterozygotes (TG) (Fig. 
3D). Thus, the IL28B polymorphism might differentially regulate the expression of ISGs in the 
liver, leading to the different treatment outcomes.   
We performed univariate and multivariate analyses to identify the clinical factors 
associated with the major and minor genotypes (Table 4). Univariate analysis showed that 
higher hepatic ISGs and lower BMI were significantly associated with the minor genotype; 
however, multivariate analysis showed that only hepatic ISGs (≧3.5) were associated with the 
minor genotype (p<0.001, Odds ratio=18.1, 95% CI=3.95–113). We further compared the 
predictive capacity of multivariate models using the expression of hepatic ISGs (<3.5 vs. ≧
3.5) or the IL28B genotype (major vs. minor) (Supplemental Table 6). The predictive 
performance and fitness of the multivariate model using the IL28B genotype was superior to 
that using the expression of hepatic ISGs. However, when these factors were included in the 
same model, the expression of hepatic ISGs was still useful for the predictive model 
independent of the IL28B genotype (Supplemental Table 6). 
To further examine the different hepatic gene expression of patients with the major or 
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minor genotypes, pathway analysis of differentially expressed genes between the two groups 
was performed. By comparing the expression of hepatic genes between patients with the 
major and minor genotypes, 1359 differentially expressed genes were identified (p<0.01; 711 
genes were up-regulated with the minor genotype and 648 genes were up-regulated with the 
major genotype). Pathway analysis of these genes demonstrated that signaling pathways 
related to interferon action, apoptosis, and Wnt signaling were up-regulated in the liver of 
patients with the minor genotype, while B-cell-, dendritic cell-, and NK cell-related genes were 
up-regulated in the liver of patients with the major genotype (Supplemental Fig. 3). These 
results suggest that IL28B may be involved in innate and adaptive immune responses, and 
different anti-viral signaling pathways might be involved in the liver of patients with different 
SNPs.  
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Discussion  
 Multiple viral and host factors may be related to the treatment response to Peg-IFN 
and RBV combination therapy. For the viral factors, a higher number of aa substitutions in the 
ISDR of NS5A was strongly associated with a favorable response to IFN-α monotherapy in 
patients with genotype-1 HCV.4  
 Besides viral factors, host factors such as age, gender, fibrotic stage of the liver, and 
the presence of steatosis and insulin resistance were associated with the treatment 
outcome.20 Analysis of hepatic gene expression demonstrated that the up-regulation of ISGs 
in the liver before treatment may be related to a poor treatment response.6–9 To reveal the 
underlying mechanism of treatment resistance, two reports compared gene expression 
profiling in the liver before and during therapy, and showed that patients with up-regulated 
ISGs in the liver prior to treatment failed to further induce ISGs following the administration of 
IFN and could not eliminate HCV.6, 7 We performed a similar analysis and observed that these 
findings were more evident in liver lobular cells than in infiltrating lymphocytes in the portal 
area (submitted for publication). Thus, both viral and host factors might be closely related to 
the treatment response to Peg-IFN and RBV combination therapy. However, the clinical 
relevance and relationships of these factors have not been fully evaluated. In this study, we 
validated the clinical significance of the expression of hepatic ISGs on treatment outcome 
using a relatively large cohort of patients and compared its significance with other viral and 
host factors. To compare the patients with SVR, TR, and NR, we assessed the overall 
plausibility of each group using Fisher’s C statistic,16 and patients with SVR and TR were 
grouped together for further analysis.  
 We examined hepatic gene expression in 91 of 168 patients using the Affymetrix 
genechip. Expression profiling using 37 representative ISGs (see Material and Methods), 
which were selected from gene expression profiling comparing pretreatment and under 
treatment liver, differentiated two groups of patients: the Up-ISG and Down-ISG groups (Fig. 
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1). The proportion of patients with NR to treatment was significantly higher in the Up-ISGs 
group.   
 Multivariate analysis showed that hepatic ISGs (<3.5), fibrosis stage (F1-2), and 
ISDR mutations (≧2) significantly contributed to the outcome for the SVR+TR group (Table 1). 
Discriminate analysis using variables selected by multivariable analysis predicted the 
SVR+TR patients with 82% accuracy and NR patients with 79% accuracy. However, the 
accuracy decreased to 67% for SVR+TR patients and 53% for NR patients when the 
expression of hepatic ISGs was removed from the variables (data not shown). Interestingly, 
the expression of hepatic ISGs was strongly correlated with γ-GTP and weakly correlated with 
insulin resistance. A recent study describing the association between insulin resistance and 
poor treatment outcome might be partially explained by this observation.20 
In this study, we utilized 3 ISGs (Mx1, IFI44, and IFIT1) out of 15 validated by 
RTD-PCR. The expression values of these ISGs were higher than those of other ISGs 
(Supplemental Fig. 1A). We averaged these ISGs and set the cut-off value as 3.5 from the 
ROC curve (Supplemental Fig. 1B). The sensitivity, specificity, and positive and negative 
predictive values on the likelihood of achieving SVR+TR using this cut-off value were 82% 
(103/125), 72% (31/43), 90% (103/115), and 58% (31/53), respectively. The results were 
compared with those observed for the 15 ISGs (Supplemental Table 5). These results showed 
that the 3.5 cut-off value for Mx1, IFI44, and IFIT1 would be valuable for clinical use. 
 Despite the importance of the expression of hepatic ISGs, viral factors may also allow 
us to predict the outcome of treatment. Multivariate analysis showed that ISDR mutations (≧2) 
independently contributed to the treatment outcome, although univariate analysis did not 
show significance (p=0.07); therefore, ISDR might be uniquely and differentially involved in 
treatment resistance.  
 What causes the differences in the expression of hepatic ISGs? In parallel to the 
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gene expression analysis, a GWAS was applied to identify genomic loci associated with 
treatment response, and a polymorphism in IL28B was found to predict hepatitis C 
treatment-induced viral clearance.10–12 To examine the relationship between the genetic 
variation of IL28B and hepatic gene expression, we determined the IL28B polymorphism in 91 
patents (Table 3). The patients with the minor genotype (TG or GG) had an increased 
expression of hepatic ISGs compared with the patients with major genotype (TT) (Figs. 2, 3). 
In European-Americans, the proportion of major homozygotes is 39% (CC at rs1297986), 
49% for heterozygotes (TC), and 12% for minor homozygotes (TT).11 Although the proportion 
of minor homozygotes was much less in this study (GG=4%), as reported in a previous study 
in Japan,12 more patients are required for proper evaluation. It is interesting that the 
expression of hepatic ISGs in minor homozygotes (GG) was higher than in heterozygotes 
(TG) in this study.  
The results clearly showed that the differences in the expression of hepatic ISGs 
before treatment are associated with the IL28B polymorphism and results in different 
treatment outcomes. Although we could not detect significant differences in the expression 
levels of IL28B depending on the different SNP, some patients with the major genotype 
showed a higher expression of IL28B. As IL28B expression was approximately tenfold less 
than the expression of ISGs, the lower expression of IL28B may be a reason for the 
decreased ability to distinguish differences in its expression. Another possibility may be the 
specificity of the IL28B primers used in this study; as IL28B shares a 98.2% nucleotide 
sequence homology with IL28A, IL28B specific primers are not available.21 When the 
expression of IL28B and hepatic ISGs were compared, a significant correlation was observed 
and, interestingly, IL28B and ISGs derived from different SNPs were correlated in a different 
way (Figs. 3C, D). It appeared that hepatic ISGs were more induced by the reduced amounts 
of IL28B in patients with the minor genotype. The mechanism behind these findings has yet to 
be determined; however, IL28B interacts with a heterodimeric class II cytokine receptor that 
Honda et al 
 
 - 19 -  
consists of IL-10 receptor β (IL-10Rβ) and IL-28 receptor α (IL-28Rα).18, 19 It is possible that 
IL28B could mediate anti-viral signaling through IL-10 signaling as well as STAT1 activation. 
The Th2 dominant signaling of IL28B may modulate signaling pathways in livers with CH-C 
and contributes to the different expression of ISGs. Another possibility may be that the cell 
origin of hepatic ISGs is different. A recent study revealed cell-type specific ISG expression in 
macrophages and hepatocytes, which could be related to the IFN response.22 As more of the 
B-cell-, dendritic cell-, and NK cell-related genes were up-regulated in the liver of patients with 
the major genotype, ISGs could be expressed by these cells, while they are expressed by 
hepatocytes in the liver of patients with the minor genotype. It is known that the induction of 
ISGs in lymphocytes is lower than that in hepatocytes. The precise mechanism should be 
investigated further as a different regulatory mechanism for the expression of ISGs may be 
present. 
 In conclusion, we presented the clinical relevance of the expression of hepatic ISGs 
for the treatment outcome of Peg-IFN and RBV combination therapy. The different 
expressions of hepatic ISGs before treatment might be due to polymorphisms in IL28B. 
Further studies are required to clarify the detailed pathways of IL28B and hepatic gene 
expression through molecular biological and immunological aspects.   
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Figure Legends 
Figure 1 
Hierarchical clustering analysis of 91 patients using 37 representative ISGs. Responses to 
therapy (SVR, TR, and NR), fibrosis stage (F1-4), and status; ISDR mutations are also shown. 
ISDR mutation≧2=M, ≦1=0. 
 
Figure 2 
Hierarchical clustering analysis of 91 patients with the defined genotype of IL28B. 
Responses to therapy (SVR, TR, and NR) and IL28B genotype (TT, TG, or GG) are shown. 
The structure of the dendrogram and heatmap is the same as in Figure 1. 
 
Figure 3 
A: IL28 expression in the liver of 91 patients with the major (TT) or minor (TG or GG) 
genotype (rs8099917). 
B: Expression of ISGs in the liver of patients with the major (TT) or minor (TG or GG) 
genotype (rs8099917). 
C: Relationship between IL28 and ISGs in the liver of patients with the major (TT) genotype 
(rs8099917). 
D: Relationship between IL28 and ISGs in the liver of patients with the minor (TG or GG) 
genotype (rs8099917). 
 
Supplemental Figure 1 
A: Box plots of ISG expression in 168 patients detected by RTD-PCR. 
B: Receiver operating characteristic (ROC) curve and area under the curve (AUC) of ISGs on 
the likelihood of achieving SVR+TR.  
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Supplemental Figure 2 
Relationship of the expression of hepatic ISGs and HCV-RNA with different treatment 
responses (SVR or TR vs. NR). 
 
Supplemental Figure 3 
Pathway analysis of differentially expressed genes in the liver of patients with the major (TT) 
or minor (TG or GG) genotype (rs8099917) using MetaCore. The frequently observed 


















Comparison of clinical factors between patients with and without NR





No. of patients n=125 n=43 -
Age and gender
Age (y) 57 (30–72) 56 (30–73) 0.927 -
Sex (M vs. F) 68 vs. 57 24 vs. 19 0.872 -
Liver factors
F stage (F1-2 vs. F3-4) 95 vs. 30 20 vs. 23 0.001 4.18 (1.61–11.5) 0.003
A grade (A0-1 vs. A2-3) 68 vs. 57 19 vs. 24 0.248 -
ISGs (Mx, IFI44, IFIT1)
(<3.5 vs.≧3.5) 103 vs. 22 12 vs. 31 <0.001 16.2 (6.21–47.8) <0.001
Laboratory parameters
HCV-RNA (KIU/ml) 2300 (126–5000) 1930 (140–5000) 0.725 -
BMI (kg/m2) 23.2 (16.3–34.7) 23.4 (19.5–40.6) 0.439 - 0.107
AST (IU/L) 46 (18–258) 64 (21–283) 0.017 -
ALT (IU/L) 60 (16–376) 82 (18–345) 0.052 -
γ-GTP (IU/L) 36 (4–367) 75 (26–392) <0.001 -
WBC (/mm3) 4800 (2100–11100) 4800 (2500–8200) 0.551 -
Hb (g/dl) 14 (9.3–16.6) 14.4 (11.2–17.2) 0.099 -
PLT (×104/mm3) 15.7 (7–39.4) 15.2 (7.6–27.8) 0.378 -
TG (mg/dl) 98 (30–323) 116 (45–276) 0.058 -
T-Chol (mg/dl) 167 (90–237) 160 (81–214) 0.680 -
LDL-Chol (mg/dl) 82 (36–134) 73 (29–123) 0.019 -
HDL-Chol (mg/dl) 42 (20–71) 47 (18–82) 0.098 -
FBS (mg/dl) 94 (60–291) 96 (67–196) 0.139 -
Insulin (µU/ml) 6.6 (0.7–23.7) 6.8 (2–23.7) 0.039 -
HOMA-IR 1.2 (0.3–11.7) 1.2 (0.4–7.2) 0.697 -
Viral factors
ISDR mutations ≦1 vs. ≧2 80 vs. 44 34 vs. 9 0.070 5.09 (1.69–17.8) 0.003
Treatment factors
Total dose administered
Peg-IFN (µg) 3840 (960–7200) 3840 (1920–2880) 0.916 -
RBV (g) 202 (134–336) 202 (36–336) 0.531 -
Achieved administration rate
Peg-IFN (%)
≧80% 84 28 0.975 -
<80% 42 14
RBV (%)
≧80% 76 24 0.745 -
<80% 50 18
Achievement of EVR 101/125 (81%) 0/43 (0%) <0.001 -
BMI, body mass index; AST, aspartate aminotransferase
ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase
WBC, leukocytes; Hb, hemoglobin; PLT, platelets; TG, triglycerides
T-chol, total cholesterol; LDL-chol, low density lipoprotein cholesterol












β p value β p value
AST (IU/L) 0.274 0.13 0.42 <0.001 - - -
γ-GTP (IU/L) 0.326 0.18 0.47 <0.001 0.288 0.14 0.43 <0.001
HCV-RNA (KIU/ml) -0.170 -3.19 -0.02 0.025 -0.255 -0.40 -0.11 <0.001
SVR+TR -0.237 -0.32 -0.05 0.009 - - -
NR -0.168 -0.57 0.18 0.298 - - -
FBS (mg/dl) 0.182 0.03 0.35 0.021 - - -
Insulin (µU/ml) 0.190 0.03 0.34 0.016 - - -
HOMA-IR 0.181 0.03 0.33 0.017 - - - 0.073
TG (mg/dl) 0.201 0.05 0.35 0.011 - - - 0.089
LDL-Chol (mg/dl) -0.177 -0.33 -0.02 0.025 -0.143 -0.28 0.00 0.048
γ-GTP, gamma-glutamyl transpeptidase; AST, aspartate aminotransferase
FBS, fasting blood sugar; TG, triglycerides
LDL-chol, low density lipoprotein cholesterol
CI, confidence interval
β, βcoefficient  
CI, confidence interval
95% CI 95% CI
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Table 3 Clinical characteristics of 32 patients genotyped by GW AS and 5 SNPs in strong linkage disequilibrium with IL28B, including rs12979860 11)












allele C G T G A
1 SVR 42 M 1 4.20 83.8 TT AA CC TT GG
2 SVR 59 M 1 2.62 45.5 TT AA CC TT GG
3 SVR 41 F 1 1.54 1.3 TT AA CC TT GG
4 TR 57 M 1 3.18 21.7 TT AA CC TT GG
5 TR 68 F 1 1.43 20.3 TT AA CC TT GG
6 SVR 44 M 1 0.97 4.6 TT AA CC TT GG
7 SVR 61 M 2 2.15 6.1 TT AA CC TT GG
8 SVR 50 M 2 3.25 66.4 TT AA CC TT GG
9 SVR 49 M 2 1.25 ND TT AA CC TT GG
10 TR 59 F 2 1.29 17.4 TT AA CC TT GG
11 SVR 48 F 2 1.00 90.2 TT AA CC TT GG
12 TR 65 F 2 2.86 36.4 TT AA CC TT GG
13 NR 34 M 3 0.82 17.8 TT AA CC TT GG
14 SVR 55 M 3 0.83 13.8 TT AA CC TT GG
15 TR 68 M 3 0.75 20.6 TT AA CC TT GG
16 SVR 64 M 3 0.94 15.7 TT AA CC TT GG
17 SVR 67 F 3 1.50 25.7 TT AA CC TT GG
18 SVR 48 M 4 1.69 7.9 TT AA CC TT GG
19 NR 66 F 1 4.57 16.5 TC AG CT TG GA
20 SVR 52 F 1 5.23 29.3 TC AG CT TG GA
21 NR 55 F 1 8.25 57.2 TC AG CT TG GA
22 SVR 49 F 1 5.36 ND TC AG CT TG GA
23 TR 44 M 1 2.08 7.0 TC AG CT TG GA
24 NR 63 M 1 2.77 10.5 TC AG CT TG GA
25 NR 61 F 2 3.98 39.1 TC AG CT TG GA
26 NR 42 M 2 4.89 5.9 TC AG CT TG GA
27 SVR 49 M 3 3.31 6.9 TC AG CT TG GA
28 TR 71 F 3 5.53 27.3 TC AG CT TG GA
29 TR 63 M 3 3.40 33.5 TC AG CT TG GA
30 NR 70 F 3 4.78 8.1 TC AG CT TG GA
31 TR 62 F 3 3.53 14.0 TC AG CT TG GA
32 NR 56 M 4 7.37 30.8 CC GG TT GG AA
The Pearson correlation of the r2 estimates for adjacent pairs; rs8099917 vs. rs8105790, rs8099917 vs. rs11881222, rs8099917 vs. rs12979860,
and rs8099917 vs. rs7248668=0.99, 0.99, 0.98, and 0.97, respectively.
 




Comparison of clinical factors between patients with major (TT) and minor (TG+GG) alleles





No. of patients n=60 n=31 -
Treatment response
SVR+TR vs NR 51 vs. 9 11 vs. 20 <0.001 -
Age and gender
Age (y) 56 (30–69) 56 (30–71) 0.843 -
Sex (M vs. F) 39 vs. 21 19 vs. 12 0.518 -
Liver factors
F stage (F1-2 vs. F3-4) 36 vs. 24 23 vs. 17 0.905 -
A grade (A0-1 vs. A2-3) 27 vs. 33 20 vs. 11 0.075 -
ISGs (Mx, IFI44, IFIT1)
(<3.5 vs.≧3.5) 46 vs. 14 5 vs. 26 <0.001 18.1 (3.95–113) <0.001
Laboratory parameters
HCV-RNA (KIU/ml) 2055 (160–5000) 1970 (126–5000) 0.602 -
BMI (kg/m2) 24.5 (16.3–40.5) 22.9 (19.1–26.6) 0.006 - 0.077
AST (IU/L) 59 (22–258) 54 (21–283) 0.227 -
ALT (IU/L) 75 (24–376) 60 (18–236) 0.077 -
γ-GTP (IU/L) 61 (4–392) 53 (20–229) 0.517 - 0.167
WBC (/mm3) 4450 (2100–11100) 4600 (2500–8200) 0.947 -
Hb (g/dl) 14.2 (11.4–16.7) 14.5 (11.2–17.2) 0.606 -
PLT (×104/mm3) 15.4 (7–39.4) 16.2 (9.2–27.7) 0.832 -
TG (mg/dl) 98 (58–248) 131 (30–303) 0.053 - 0.055
T-Chol (mg/dl) 172 (115–222) 168 (129–237) 0.910 -
LDL-Chol (mg/dl) 84 (42–123) 69 (51–107) 0.052 - 0.055
HDL-Chol (mg/dl) 44 (18–72) 45 (29–77) 0.218 -
FBS (mg/dl) 95 (59–291) 96 (66–206) 0.849 -
Insulin (µU/ml) 7.5 (0.7–23.2) 9.2 (2–23.2) 0.195 -
HOMA-IR 1.3 (0.3–11.7) 1.2 (0.4–9.6) 0.339 -
Viral factors
ISDR mutations (≦1 vs. ≧2) 38 vs. 22 23 vs. 7 0.194 - 0.083
Treatment factors
Todal dose adminstrated
Peg-IFN (µg) 3960 (1500–7200) 3840 (1920–5760) 0.377 -
RBV (g) 203 (26–336) 201 (106–268) 0.777 -
Achieved administration rate
Peg-IFN (%)
≧80% 41 17 0.207 -
<80% 19 14
RBV (%)
≧80% 34 19 0.671 -
<80% 26 12
Achievement of EVR 40/60 (62%) 9/31 (29%) <0.001 -
BMI, body mass index; AST, aspartate aminotransferase
ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase
WBC, leukocytes; Hb, hemoglobin; PLT, platelets; TG; triglycerides
T-chol, total cholesterol; LDL-chol, low density lipoprotein cholesterol
HDL-chol, high density lipoprotein cholesterol; FBS; fasting blood sugar




























































































































































































































































































































































































Hect domain and RLD 5
DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like
IFN-induced protein with tetratricopeptide repeats 5
Tripartite motif-containing 69
SP110 nuclear body protein
Sterile alpha motif domain containing 9
N-myc (and STAT) interactor
Tudor domain containing 7
Polyribonucleotide nucleotidyltransferase 1
IFN-induced protein with tetratricopeptide repeats 2
5'-nucleotidase, cytosolic III
2',5'-oligoadenylate synthetase 1, 40/46kDa
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
eIF2-alpha kinase 2
EST(238743_at)
IFN induced transmembrane protein 1 (9-27)
Receptor transporter protein 4
IFN-induced protein with tetratricopeptide repeats 3
Hect domain and RLD 6
UMP-CMP kinase 2, mitochondrial
Phospholipid scramblase 1
IFN induced with helicase C domain 1
Ubiquitin specific peptidase 18
ISG15 ubiquitin-like modifier
XIAP associated factor 1
IFN-induced protein 44
IFN-induced protein with tetratricopeptide repeats 1
Radical S-adenosyl methionine domain containing 2
IFN-induced protein 44-like
2'-5'-oligoadenylate synthetase 2, 69/71kDa
Mx1
2'-5'-oligoadenylate synthetase 3, 100kDa
Poly (ADP-ribose) polymerase family, member 9







Hect domain and RLD 5
DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like
IFN-induced protein with tetratricopeptide repeats 5
Tripartite motif-containing 69
SP110 nuclear body protein
Sterile alpha motif domain containing 9
N-myc (and STAT) interactor
Tudor domain containing 7
Polyribonucleotide nucleotidyltransferase 1
IFN-induced protein with tetratricopeptide repeats 2
5'-nucleotidase, cytosolic III
2',5'-oligoadenylate synthetase 1, 40/46kDa
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
eIF2-alpha kinase 2
EST(238743_at)
IFN induced transmembrane protein 1 (9-27)
Receptor transporter protein 4
IFN-induced protein with tetratricopeptide repeats 3
Hect domain and RLD 6
UMP-CMP kinase 2, mitochondrial
Phospholipid scramblase 1
IFN induced with helicase C domain 1
Ubiquitin specific peptidase 18
ISG15 ubiquitin-like modifier
XIAP associated factor 1
IFN-induced protein 44
IFN-induced protein with tetratricopeptide repeats 1
Radical S-adenosyl methionine domain containing 2
IFN-induced protein 44-like
2'-5'-oligoadenylate synthetase 2, 69/71kDa
Mx1
2'-5'-oligoadenylate synthetase 3, 100kDa
Poly (ADP-ribose) polymerase family, member 9















































































































































































































































































































































































Clinical characteristics of patients enrolled in this study
Clinical category SVR TR NR
No. of patients n=70 n=55 n=43
Age and gender
Age (y) 55 (30–72) 60 (35–72) 57 (30–73)
Sex (M vs. F) 41 vs. 29 27 vs. 28 24 vs. 19
Liver factors
F stage (F1-2 vs. F3-4) 56 vs. 14 39 vs. 16 20 vs. 23
A grade (A0-1 vs. A2-3) 39 vs. 31 29 vs. 26 19 vs. 24
ISGs (Mx, IFI44, IFIT1) 1.89 (0.36–9.48) 1.65 (0.44–7.69) 4.84 (0.82–17.3)
Laboratory parameters
HCV-RNA (KIU/ml) 1800 (126–5000) 2600 (400–5000) 1930 (140–5000)
BMI (kg/m2) 23.7 (16.3–32.8) 22.8 (18.7–34.7) 23.4 (19.5–40.6)
AST (IU/L) 47 (20–258) 46 (18–205) 64 (21–283)
ALT (IU/L) 61 (17–341) 57 (16–376) 82 (18–345)
γ-GTP (IU/L) 38 (4–270) 34 (12–367) 75 (26–392)
WBC (/mm3) 4700 (2400–11100) 4900 (2100–7600) 4800 (2500–8200)
Hb (g/dl) 14.3 (9.3–16.6) 13.5 (9.3–16.4) 14.4 (11.2–17.2)
PLT (×104/mm3) 16.2 (7–39.4) 15.2 (7.6–27.8) 15.2 (7.6–27.8)
TG (mg/dl) 99 (30–303) 92 (42–323) 116 (45–276)
T-Chol (mg/dl) 171 (116–237) 163 (90–229) 160 (81–214)
LDL-Chol (mg/dl) 87 (42–134) 77 (36–122) 73 (29–123)
HDL-Chol (mg/dl) 43 (27–67) 40 (20–71) 47 (18–82)
FBS (mg/dl) 97 (60–221) 93 (65–291) 96 (67–196)
Insulin (µU/ml) 7.1 (0.7–22) 6.7 (2–13.3) 6.8 (2–23.7)
HOMA-IR 1.3 (0.3–11.7) 1.1 (0.4–6.2) 1.2 (0.4–7.2)
Viral factors
ISDR mutations ≦1 vs. ≧2 35 vs. 34 45 vs. 10 34 vs. 9
Treatment factors
Total dose administered
Peg-IFN (µg) 3840 (960–7200) 3840 (1500–5760) 3840 (1920–2880)
RBV (g) 201 (13–336) 202 (36–285) 202 (36–336)
Achieved administration rate
Peg-IFN (%)
≧80% 51 33 28
<80% 20 22 14
RBV (%)
≧80% 47 29 24
<80% 24 26 18
Achievement of EVR 65/70 (93%) 36/55 (65%) 0/43 (0%)
Data are expressed as median (range)
BMI, body mass index; AST, aspartate aminotransferase
ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase
WBC, leukocytes; Hb, hemoglobin; PLT, platelets; TG, triglycerides
T-chol, total cholesterol; LDL-chol, low density lipoprotein cholesterol
HDL-chol, high density lipoprotein cholesterol; FBS, fasting blood sugar  
 
 




Overall plausibility of the treatment response groups is assessed using Fisher’s C statistic 
Clinical category SVR vs. NR SVR vs. TR TR vs. NR SVR vs. TR+NR SVR+TR vs. NR
Age and gender
Age (y) 0.498 0.004 0.300 0.014 1.000
Sex (M vs. F) 1.000 0.648 1.000 0.803 1.000
Liver factors
F stage (F1-2 vs. F3-4) 0.002 0.284 0.012 0.011 0.002
A grade (A0-1 vs. A2-3) 0.504 1.000 0.940 0.778 0.495
ISGs (Mx, IFI44, IFIT1) 0.002 1.000 0.002 0.004 0.001
Laboratory parameters
HCV-RNA (KIU/ml) 0.602 0.008 0.340 0.083 1.000
BMI (kg/m2) 0.768 0.962 0.330 1.000 0.878
AST (IU/L) 0.008 0.970 0.047 0.148 0.035
ALT (IU/L) 0.032 1.000 0.093 0.154 0.104
γ-GTP (IU/L) 0.004 1.000 0.003 0.336 0.002
WBC (/mm3) 0.974 0.598 1.000 1.000 1.000
Hb (g/dl) 0.606 0.236 0.033 0.774 0.198
PLT (×104/mm3) 0.238 0.436 1.000 0.416 0.756
TG (mg/dl) 0.354 0.124 1.000 1.000 0.116
T-Chol (mg/dl) 1.000 0.556 0.042 0.518 1.000
LDL-Chol (mg/dl) 0.018 0.626 0.232 0.072 0.039
HDL-Chol (mg/dl) 0.356 0.316 0.070 1.000 0.196
FBS (mg/dl) 0.688 0.828 0.236 1.000 0.277
Insulin (µU/ml) 0.014 1.000 0.018 1.000 0.078
HOMA-IR 0.102 1.000 0.066 0.944 1.000
Viral factors
ISDR mutations ≦1 vs. ≧2 0.004 0.002 1.000 0.002 0.139
Statistics (Fisher's C) 97.748 51.196 88.204 65.599 81.059
Probability 0.000 0.156 0.000 0.011 0.000
Fisher's C is defined by C=-2∑ln (pi) where pi is the probability (p-values) of each independent statement (clinical factors)















Clinical characteristics of patients analyzed by genechip
Clinical category Data Range
No. of patients n=91
Age and gender
Age (y) 56 (21–73)




F stage (1/2/3/4) 32/23/25/11
A grade (A0-1 vs. A2-3) 47 vs. 44
ISGs (Mx, IFI44, IFIT1) 3.3 (0.6–17.3)
Laboratory parameters
HCV-RNA (KIU/ml) 2000 (126–5000)
BMI (kg/m2) 23.8 (16.2–40.6)
AST (IU/L) 56 (20–283)
ALT (IU/L) 71 (16–376)
γ-GTP (IU/L) 58 (4–392)
WBC (/mm3) 4500 (2100–11100)
Hb (g/dl) 14.3 (11.2–17.2)
PLT (×104/mm3) 15.6 (6.6–39.4)
TG (mg/dl) 109 (30–303)
T-Chol (mg/dl) 171 (114–237)
LDL-Chol (mg/dl) 79 (42–123)
HDL-Chol (mg/dl) 44 (18–77)
FBS (mg/dl) 97 (59–291)
Insulin (µU/ml) 6.7 (0.7–23.2)
HOMA-IR 1.1 (0.3–11.7)
Viral factors
ISDR mutations ≦1 vs. ≧2 61 vs. 29
Treatment factors
Total dose administered
Peg-IFN (µ/kg) 3840 (1500–7200)








Achievement of EVR 49/90 (54%)
BMI, body mass index; AST, aspartate aminotransferase
ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase
WBC; leukocytes, Hb; hemoglobin, PLT; platelets, TG; triglycerides
T-chol, total cholesterol; LDL-chol, low density lipoprotein cholesterol
HDL-chol, high density lipoprotein cholesterol; FBS, fasting blood sugar
 




Pairwise comparison of the expression of 15 ISGs in 168 patients 




IFI44L 0.88 0.88 0.90
OAS2 0.82 0.83 0.90 0.94
USP18 0.85 0.84 0.93 0.94 0.94
RSAD2 0.89 0.89 0.92 0.96 0.92 0.95
IFIT1 0.92 0.89 0.85 0.90 0.84 0.88 0.93
IFIH1 0.82 0.85 0.92 0.92 0.92 0.92 0.93 0.87
XAF1 0.81 0.79 0.88 0.89 0.91 0.88 0.90 0.82 0.89
CMPK2 0.93 0.92 0.88 0.94 0.89 0.92 0.96 0.92 0.90 0.86
EPSTI1 0.83 0.85 0.89 0.90 0.92 0.90 0.91 0.84 0.91 0.87 0.90
HERC6 0.88 0.87 0.93 0.95 0.94 0.94 0.96 0.89 0.93 0.91 0.95 0.92
PARP9 0.78 0.80 0.62 0.66 0.61 0.62 0.67 0.72 0.68 0.62 0.74 0.64 0.66
PLSCR1 0.79 0.83 0.80 0.84 0.83 0.80 0.82 0.78 0.84 0.77 0.82 0.81 0.84 0.66
MX+IFI44+IFIT1 0.96 0.93 0.94 0.94 0.89 0.93 0.96 0.97 0.91 0.87 0.95 0.90 0.94 0.74 0.83












Sensitivity, specificity, and positive and negative predictive values of 15 ISGs on the likelihood of achieving SVR+TR.
Cut off Sensitivity Specificity PPV NPV 
MX+IFI44+IFIT1 3.5 0.82 0.72 0.90 0.58
103/125 31/43 103/115 31/53
MX 3.5 0.80 0.67 0.88 0.54
99/123 28/42 99/113 28/52
OAS3 1.5 0.74 0.71 0.88 0.48
91/123 29/41 91/103 29/61
IFI44 3.5 0.78 0.71 0.88 0.54
91/117 30/41 91/103 30/56
IFI44L 1.5 0.80 0.68 0.88 0.53
98/123 28/41 98/111 28/53
OAS2 1.5 0.74 0.73 0.89 0.48
91/123 30/41 91/102 30/60
USP18 1.5 0.80 0.68 0.88 0.54
99/123 28/41 99/112 28/52
RSAD2 1.5 0.77 0.73 0.90 0.50
99/129 30/41 99/110 30/60
IFIT1 3.5 0.80 0.71 0.89 0.56
99/123 30/42 99/111 30/54
IFIH1 1.5 0.81 0.61 0.86 0.52
100/123 25/41 100/116 25/48
XAF1 2 0.73 0.78 0.91 0.49
90/123 32/41 90/99 32/65
CMPK2 2 0.75 0.71 0.88 0.48
92/123 29/41 92/104 29/60
EPSTI1 2 0.72 0.78 0.91 0.48
88/123 32/41 88/97 32/67
HERC6 1.5 0.78 0.76 0.91 0.53
96/123 31/40 96/106 31/58
PARP9 2 0.90 0.44 0.83 0.60
111/123 18/41 111/134 18/30
PLSCR1 1.3 0.85 0.51 0.84 0.54
105/123 21/41 105/125 21/39
 
 




Variables Category Odds (95% CI) p-value AIC AUC
Multivariate model with ISGs ISGs <3.5 vs. ≧3.5 25.1 (6.03–176) <0.001
(n=91) BMI <25 vs. ≧25 kg/m2 4.13 (0.89–29.9) 0.071
ISDR mutations ≦1 vs. ≧2 3.07 (0.81–14.1) 0.102
F stage F1-2 vs. F3-4 2.48 (0.73–9.25) 0.146
Multivariate model with IL28B IL28B Major vs. Minor 35.2 (8.19–259) <0.001
(n=91) F stage F1-2 vs. F3-4 3.31 (0.90–14.3) 0.070
BMI <25 vs. ≧25 kg/m2 4.01 (0.85–29.3) 0.081
ISDR mutations ≦1 vs. ≧2 2.39 (0.50–14.1) 0.280
Multivariate model with ISGs and IL28B IL28B Major vs. Minor 19.5 (3.69–176) <0.001
(n=91) ISGs <3.5 vs. ≧3.5 11.3 (2.12–90.9) 0.004
BMI <25 vs. ≧25 kg/m2 12.2 (1.82–163) 0.008
F stage F1-2 vs. F3-4 3.14 (0.79–15.4) 0.106
ISDR mutations ≦1 vs. ≧2 2.76 (0.55–18.0) 0.224
CI, confidence interval
AIC, Akaike's information criterion; AIC=-2lnL+2k (L=maximum likelihood, k=the number of fitted parameters in the model)
AUC, area under the curve of a receiver operating characteristic 














































































































































































































































































































































































































































































































































































































































AUC=0.79 AUC=0.77 AUC=0.80 AUC=0.78
AUC=0.79 AUC=0.79 AUC=0.78
AUC=0.80
AUC=0.78 AUC=0.79 AUC=0.78 AUC=0.78
AUC=0.80 AUC=0.72 AUC=0.76 AUC=0.82
OAS3 IFI44 IFI44L
OAS2 USP18 RSAD2 IFIT1
IFIH1 XAF1 CMPK2 EPSTI1
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